Sutent (sunitinib malate) - Cases of severe skin reactions

Pfizer Canada Inc. (manufacturer of Sutent), in collaboration with Health Canada, would like to inform you about an important revision to the Product Monograph, including the consumer information section, for Sutent (sunitinib malate). Sutent is indicated for the treatment of gastrointestinal stromal tumour after failure of imatinib mesylate treatment due to resistance or intolerance. It is also indicated for the treatment of metastatic renal cell carcinoma of clear cell histology and for the treatment of patients with unresectable locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumours, whose disease is progressive. A statement has been recently added to the Product Monograph to inform Health Care Professionals and patients about a potential association between the use of Sutent and severe cutaneous reactions suggestive of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Read more here.